Prof Andrew Abell launches Calpain Therapeutics to commercialise cataract drug

The innovators behind commercialising a world-first drug to slow cataract growth and to delay cataracts from forming, have been named as one of five finalists in The University of Queensland (UQ) Business Schools $100,000 Enterprize business plan competition.

The drug being commercially developed by Adelaide-based Calpain Therapeutics targets a protein in the eyes tissue. This protein, when activated by various triggers, including those associated with the bodys  ageing, causes the clouding of the eyes lens, known as a cataract.  Severe cataracts are the leading cause of blindness around the world. Although most cataracts develop as people get older, they can  also be caused by diabetes, eye injury, exposure to ultraviolet light  from sunlight, long-term use of steroid medication, smoking and heavy drinking. The International Agency for the Prevention of Blindness estimates that almost 18 million people are blind from cataracts.   Many of those are in the world poorer regions.

Currently there are no drops or medications to prevent or reverse cataracts. The only treatment is to have the cloudy lens surgically  removed and replaced with a synthetic lens. More than 200,000  cataract surgeries are performed in Australia each year and about 3.4 million a year in the United States. There are often long waiting  lists in public hospitals for the surgery.  Testing of the lead drug compound being advanced by Calpain  Therapeutics has shown that it significantly slows cataract  progression.

Our drug could be either drops or a cream that you put in your eyes each night before you go to sleep says Calpain Therapeutics  founding CEO and Managing Director, Dr Tim Lovell.  Through a routine eye exam, optometrists and ophthamologists can  see  the early stages of a cataract forming, likely before the person  has any idea they have it. Once its detected, then you could start  to use the drug to slow its progress.  And because we know that if you have a cataract in one eye you will mosst likely get one in the other eye, you could start to apply   the drug to both eyes, delaying the onset of a cataract in one while  slowing the growth of the cataract that has been diagnosed.   We see it as akin to brushing your teeth each day. You do that  to prevent cavities. This would be a drop each day to prevent  cataracts.

A large team is behind the development of the drug. Professor Andrew Abell of IPAS, Professor of Chemistry at Adelaide  University, is a key inventor who has been working for the past decade on the class of compounds involved. Dr Lovell has previously worked on drug design and development with global pharmaceutical company AstraZeneca and was most recently a business development manager at BioInnovation SA in Adelaide.   He says winning the UQ Business School Enterprize competition  $100,000 prize would enable Calpain Therapeutics to do the crucial and much needed  clinical experiments.  We have ophthamologists on our advisory team who get very excited  about  what we are doing, because they havent seen anything in their  careers like this to delay the forming of cataracts, and which also  has a possible secondary effect in protecting against other eye diseases, Dr Lovell says.  All five Enterprize finalists will be interviewed by the expert judging panel on September 16 and then have their final chance to impress the judges at a Pitch Day in October, to be attended  by venture capitalists and angel investors, when the winner will be  announced.

http://calpaintherapeutics.com/
http://www.uq.edu.au/news/?article=23668
http://www.business.uq.edu.au/enterprize/media

Advertisements

Posted on September 5, 2011, in ipas, IPASnews, news. Bookmark the permalink. 7 Comments.

  1. That would be wonderful if this drug will be on the market as soon as it could be

  2. Nellie Sullivan

    This drug would be sightsaving to people with wet macular degeneration who have cataracts because I understand that surgical removal of cataracts in this case could be detrimantal…because of bleeding risk.

  3. Nellie Sullivan

    I would be interested to hear of the development of the drug and possible clinical trials, etc.

  4. You actually make it seem really easy along with your presentation however
    I to find this matter to be actually one thing that I feel I’d by no means understand. It sort of feels too complex and extremely broad for me. I’m
    having a look forward on your next put up, I will
    attempt to get the grasp of it!

  5. You should take part in a contest for one of the most useful
    websites online. I most certainly will highly recommend this blog!

  6. Having read this I thought it was extremely enlightening.
    I appreciate you taking the time and energy to put this information together.

    I once again find myself spending a lot of time both reading and commenting.
    But so what, it was still worthwhile!

  1. Pingback: New drug to slow growth of cataracts

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: